Current approaches to the management of highly sensitized kidney transplant patients

Tissue Antigens

Volumn 77, Issue 3, 2011, Pages 177-186

  Susal C ^a   Morath, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Desensitization; Human leukocyte antigen antibodies; Kidney transplantation; Presensitization

Indexed keywords

ALLOANTIBODY; BORTEZOMIB; ECULIZUMAB; HLA ANTIBODY; HLA CLASS 1 ANTIBODY; HLA CLASS 2 ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGIC AGENT; LYMPHOCYTE DEPLETING AGENT; PLACEBO; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALGORITHM; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; APHERESIS; COMPLEMENT DEPENDENT CYTOTOXICITY; DELAYED GRAFT FUNCTION; DESENSITIZATION; DRUG MEGADOSE; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HLA MATCHING; HUMAN; IMMUNOADSORPTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIZATION;

GRAFT SURVIVAL; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNIZATION; ISOANTIBODIES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 79551673557     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2011.01638.x     Document Type: Review

References (60)

1. Süsal C, Döhler B, Sadeghi M, Ovens J, Opelz G. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a Collaborative Transplant Study report. Transplantation 2009: 87: 1367-71.
2. Opelz G, Graver B, Mickey MR, Terasaki PI. Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation 1981: 32: 177-83.
3. El-Awar N, Terasaki P, Lazda V, Nikaein A, Manning C, Arnold AN. Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies. Transplant Proc 2002: 34: 2531-2.
4. Meier-Kriesche HU, Scornik JC, Susskind B, Rehman S, Schold JD. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients. Transplantation 2009: 88: 23-9.
5. Süsal C, Döhler B, Opelz G. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol 2009: 70: 569-73.
6. Süsal C, Pelzl S, Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 2003: 76: 1231-2.
7. Collaborative Transplant Study. University of Heidelberg, Germany, Accessed December 29, 2010.
8. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005: 365: 1570-6.
9. Zou Y, Heinemann FM, Grosse-Wilde H et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006: 67: 230-7.
10. Breimer ME, Rydberg L, Jackson AM et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009: 87: 549-56.
11. Reinsmoen NL, Lai CH, Heidecke H et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010: 90: 1473-7.
12. Morath C, Beimler J, Opelz G et al. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 2010: 90: 645-53.
13. Fuggle SV, Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 2008: 86: 384-90.
14. Doxiadis II, Smits JM, Persijn GG, Frei U, Claas FH. It takes six to boogie: allocating cadaver kidneys in Eurotransplant. Transplantation 2004: 77: 615-7.
15. Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009: 88: 447-52.
16. Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant 2010: 10: 449-57.
17. Zachary AA, Montgomery RA, Ratner LE et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003: 76: 1519-25.
18. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000: 70: 887-95.
19. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004: 15: 3256-62.
20. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006: 6: 346-51.
21. Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002: 2: 758-60.
22. Beimler JH, Morath C, Schmidt J et al. Successful deceased-donor kidney transplantation in crossmatch-positive patients with peritransplant plasma exchange and Rituximab. Transplantation 2009: 87: 668-71.
23. Bartel G, Wahrmann M, Regele H et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010: 10: 2033-42.
24. Stegall MD, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009: 9: 998-1005.
25. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994: 57: 553-62.
26. Glotz D, Haymann JP, Sansonetti N et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993: 56: 335-7.
27. Watanabe J, Scornik JC. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 2005: 5: 2786-90.
28. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008: 359: 242-51.
29. Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006: 1: 421-32.
30. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004: 8: 535-42.
31. Gloor JM, Cosio FG, Rea DJ et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006: 6: 1841-7.
32. Higgins RM, Bevan DJ, Carey BS et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996: 348: 1208-11.
33. Haas M, Bohmig GA, Leko-Mohr Z et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 2002: 17: 1503-8.
34. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008: 86: 1754-61.
35. Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009: 9: 201-9.
36. Wahrmann M, Haidinger M, Kormoczi GF et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010: 89: 1385-90.
37. Cascio P, Oliva L, Cerruti F et al. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol 2008: 38: 658-67.
38. Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009: 9: 231-5.
39. Stegall M, Tayyab D, Lynn C, Justin B, Patrick D, Gloor J. Terminal complement inhibition decreases early acute humoral rejection in sensitized renal transplant recipients. Am J Transplant 2010: 10 (Suppl 1): 39.
40. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005: 5: 145-8.
41. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969: 280: 735-9.
42. Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004: 78: 190-3.
43. Süsal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002: 73: 1269-73.
44. Süsal C, Ovens J, Mahmoud K et al. No association of kidney graft loss with HLA antibodies detected exclusively by sensitive Luminex single antigen testing. Transplantation 2011 (in press).
45. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 2008: 85: 1200-4.
46. van den Berg-Loonen EM, Billen EV, Voorter CE et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008: 85: 1086-90.
47. Qiu J, Cai J, Terasaki PI, El-Awar N, Lee JH. Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads. Transplantation 2005: 80: 1511-3.
48. Kinukawa T, Kato M, Terasaki PI, Ozawa M. Retrospective antibody analysis of thirty patients with kidney graft failure. Clin Transpl 2006: 291-303.
49. Dittrich E, Schmaldienst S, Derfler K. [Plasma exchange and immunoadsorption]. Wien Klin Wochenschr 2007: 119: 39-53; quiz 4.
50. Yeh JH, Chiu HC. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 2000: 247: 510-3.
51. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006: 81: 643-54.
52. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003: 3: 665-73.
53. Einecke G, Sis B, Reeve J et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009: 9: 2520-31.
54. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007: 357: 2601-14.
55. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006: 6: 262-74.
56. Zeier M, Kasiske B. Initiatives focusing on transplantation highlight talks at NKF annual meeting. Nephrol News Issues 2009: 23: 51-2.
57. Jordan SC, Vo A, Bunnapradist S et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003: 76: 631-6.
58. Higgins R, Hathaway M, Lowe D et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 2007: 84: 876-84.
59. Thielke JJ, West-Thielke PM, Herren HL et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009: 87: 268-73.
60. Haririan A, Nogueira J, Kukuruga D et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009: 9: 536-42.